(Total Views: 66)
Posted On: 08/10/2025 7:56:55 AM
Post# of 85
August 7, 2025 – OGM in Childhood Leukemia
Bionano Genomics Update: OGM Shows Promise in Rare Childhood Leukemia Cases
Here is exciting news from a peer-reviewed study led by researchers in France. The study focused on a rare and aggressive form of childhood leukemia called T-cell acute lymphoblastic leukemia (T-ALL), specifically in infants and toddlers under 3 years old, a group that’s notoriously hard to analyze due to the rarity and complexity of their cancers.
Using Bionano’s Optical Genome Mapping (OGM) technology, the researchers were able to detect important genetic changes, called structural variants, that traditional methods missed. These genetic markers help identify what’s driving the cancer and how severe it might be.
In a national review of 27 cases, OGM was part of a combined testing approach alongside targeted DNA and RNA sequencing. This multi-layered strategy uncovered distinct subgroups of patients with different risk levels, which could be crucial for tailoring treatment.
Bottom line: The study supports using OGM as a powerful add-on to standard genetic tests. It helps doctors better understand rare childhood cancers and could improve how patients are classified and treated.
Bionano Genomics Update: OGM Shows Promise in Rare Childhood Leukemia Cases
Here is exciting news from a peer-reviewed study led by researchers in France. The study focused on a rare and aggressive form of childhood leukemia called T-cell acute lymphoblastic leukemia (T-ALL), specifically in infants and toddlers under 3 years old, a group that’s notoriously hard to analyze due to the rarity and complexity of their cancers.
Using Bionano’s Optical Genome Mapping (OGM) technology, the researchers were able to detect important genetic changes, called structural variants, that traditional methods missed. These genetic markers help identify what’s driving the cancer and how severe it might be.
In a national review of 27 cases, OGM was part of a combined testing approach alongside targeted DNA and RNA sequencing. This multi-layered strategy uncovered distinct subgroups of patients with different risk levels, which could be crucial for tailoring treatment.
Bottom line: The study supports using OGM as a powerful add-on to standard genetic tests. It helps doctors better understand rare childhood cancers and could improve how patients are classified and treated.
(0)
(0)
